Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057265 · ClinicalTrials.gov registry record · Phase 3
A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00057265 is a Phase 3 study that has completed, run by Novartis.
The verdict
NCT00057265, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
This study is being conducted to compare the safety and effectiveness of the investigational medication, LdT (Telbivudine) with Lamivudine, a drug currently approved by the US, European and Asian Health Authorities for the treatment of hepatitis B infection. The results for patients taking LdT will be compared to results for patients taking Lamivudine.
Interventions
- DRUG telbivudine or lamivudine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00057265
The ClinicalTrials.gov registry entry for NCT00057265 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which telbivudine or lamivudine is the first listed.
NCT00057265 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00057265 about?
NCT00057265 is a clinical study titled "A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B". This study is being conducted to compare the safety and effectiveness of the investigational medication, LdT (Telbivudine) with Lamivudine, a drug currently approved by the US, European and Asian Health Authorities for the treatment of hepatitis B infection. The results for patients taking LdT will ...
What is the current status of trial NCT00057265?
This trial is currently completed. It is a Phase 3 study. The study started on 2003-02.
What interventions are being tested in trial NCT00057265?
The interventions under investigation include: telbivudine or lamivudine (DRUG).
Who is sponsoring clinical trial NCT00057265?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.